Ignite Creation Date:
2024-05-06 @ 9:43 AM
Last Modification Date:
2024-10-26 @ 12:18 PM
Study NCT ID:
NCT03052608
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2017-01-20
Brief Title:
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Sponsor:
Pfizer
Organization:
Pfizer
Organization Data
Organization:
Pfizer
Class:
INDUSTRY
Study ID:
B7461006
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Pfizer
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None